Market Report Source

Overview

The expansion of the EU has created exciting opportunities for pharmaceutical companies to expand into new territories and take advantage of these high growth emerging markets; this report analyzes eight of the accession countries including the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia (The A8). Pharmaceutical Growth Opportunities in the EU Accession States is a new report which provides in-depth insights into the competitive dynamics of the EU accession states. It identifies the key drivers and resistors of growth to enable you to understand the most important factors behind success in each country market. Use this latest report to determine key product opportunities, identify potential alliance partners and plan a successful and sustainable long term growth strategy to secure your leading position in the next five years.

Table of Contents

Table of Contents

Pharmaceutical Growth Opportunities in the EU

Accession States

Executive Summary

The external environment in the accession states

The market opportunity in the accession states

Market composition in the accession states

Competitive dynamics in the accession pharmaceutical markets

Chapter 1 The external environment in the accession states

Summary

Introduction

Background

Healthcare systems in the accession states

Healthcare financing in the accession states

Private and public sources of healthcare financing

Structural challenges to pharmaceutical marketers in the accession states

Healthcare delivery

Social aspects

Market factors

Pricing and reimbursement

Healthcare reform in the accession countries

EU pharmaceutical policy and its implications for accession markets

EU competition law

Intellectual property rights

Marketing approvals

Parallel importing and pricing issues

Profiles of healthcare systems across the accession states

Czech Republic

Poland

Slovenia

Slovakia

iv

Latvia

Lithuania

Estonia

Hungary

Road to reform in the accession states

Chapter 2 The market opportunity in the accession states

Summary

Introduction

Market dynamics in the accession states

Breakdown of market composition by therapeutic areas

Market breakdown by therapeutic areas over the period 2000-04: a

comparison between A8 and EU5

Key trends in the accession pharmaceutical markets: therapeutic class specific

analysis

Cardiovascular

Cardiovascular market analysis

Analysis of cardiovascular sales by country, 2000-04

Key growth drivers in the cardiovascular market

CNS

CNS market analysis

Analysis of CNS sales by country, 2000-04

Key growth drivers in the CNS market

Respiratory

Respiratory market analysis

Analysis of respiratory sales by country, 2000-04

Key growth drivers in the respiratory market

Anti-infectives

Anti-infectives market analysis

Analysis of anti-infectives sales by country, 2000-04

Key growth drivers in the anti-infectives market

Cancer

Cancer market analysis

Analysis of cancer sales by country, 2000-2004

Key growth drivers in the cancer market

Others

Analysis of sales across other therapeutic areas in the accession

countries, 2000-04

Sales forecasts in the accession pharmaceutical market by therapeutic area

v

Chapter 3 Market composition in the

accession states

Summary

Introduction

Licensing trends: a comparison with the EU5

The A8

The EU5

Current licensing trends

Licensing trends in the accession states

Other brands

Original brands

Licensed brands

Unbranded drugs

Therapeutic licensing trends in the accession states

Cardiovascular

CNS

Cancer

Anti-infectives

Respiratory

Other therapeutic areas

Future licensing trends

Chapter 4 Competitive dynamics in the accession pharmaceutical markets

Summary

Introduction

Analysis of the major pharmaceutical players in the accession states

Overview of the performance of major companies in the accession region

Strategies for success in the accession pharmaceutical market

Key regional players

Zentiva

Gedeon Richter

KRKA

Polpharma

Pliva

Key multinational players

Novartis

Sanofi-Aventis

GlaxoSmithKline

Servier

Pfizer

vi

Winning strategies in the accession pharmaceutical market

Competitive strategy of key regional players in the accession

pharmaceutical market

Competitive strategy of key multinational players in the accession

pharmaceutical market

Strategies for companies to succeed within the top therapeutic areas

Chapter 5 Appendix

Glossary

Index

List of Figures

Figure 1.1: Average total health expenditure as a proportion of GDP for EU5 and A8 regions,

2000-04

Figure 1.2: Structural challenges shaping A8 market development

Figure 1.3: Structural challenges in healthcare delivery in the A8 region

Figure 1.4: Major challenges in healthcare reform across the A8 region

Figure 1.5: Average total health expenditure as % of GDP for the Czech Republic, the A8 and the

EU5, 2000-04

Figure 1.6: Direct personal expenditure of individuals on health services in the Czech Republic,

2000-04

Figure 1.7: Cash expenditure on healthcare paid directly by individuals in the Czech Republic,

2004

Figure 1.8: Average total health expenditure as % of GDP for Poland, the A8 and the EU5, 2000-

04

Figure 1.9: Average total health expenditure as % of GDP for Slovenia, the A8 and the EU5,

2000-04

Figure 1.10: Average total health expenditure as % of GDP for Slovakia, the A8 and the EU5,

2000-04

Figure 1.11: Average total health expenditure as % of GDP for Latvia, the A8 and the EU5, 2000-

04

Figure 1.12: Average total health expenditure as % of GDP for Lithuania, the A8 and the EU5,

2000-04

Figure 1.13: Average total health expenditure as % of GDP for Estonia, the A8 and the EU5, 2000-

04

Figure 1.14: Total health expenditure as % of GDP for Hungary, the A8 and the EU5, 2000-04

Figure 1.15: Historic and present challenges in healthcare reform in the A8

Figure 2.16: Forecast A8 market composition by therapy area, 2004 and 2011

Figure 3.17: Comparison of sales in the A8 and the EU5 by product category, 2004

Figure 3.18: Comparison of sales in the A8 pharmaceutical markets by product category, 2004

Figure 3.19: Comparison of licensing sales in the A8 pharmaceutical markets, 2004

Figure 4.20: Breakdown of the leading pharmaceutical companies in the A8, 2004

Figure 4.21: Growth dynamics of the leading pharmaceutical companies in the A8, 2004

Figure 4.22: Outlook for leading pharmaceutical companies in the A8 region, 2005-11

vii

List of Tables

Table 1.1: Recent statistics on healthcare sector in the A8 markets, 2004

Table 1.2: Public and private healthcare financing in the A8 markets, 2004

Table 1.3: Summary of pricing and reimbursement policies across the A8 markets

Table 1.4: Healthcare resources in the Czech Republic, the A8 and EU5 countries, 2004

Table 1.5: Healthcare resources in Poland, the A8 and EU5 countries, 2004

Table 1.6: Estimation of expenses for healthcare services in Slovenia, 2000-03

Table 1.7: Healthcare resources in Slovenia, the A8 and EU5 countries, 2004

Table 1.8: Healthcare resources in Slovakia, the A8 and EU5 countries, 2004

Table 1.9: Healthcare resources in Latvia, the A8 and EU5 countries, 2004

Table 1.10: Healthcare resources in Lithuania, the A8 and EU5 countries, 2004

Table 1.11: Healthcare resources in Estonia, the A8 and EU5 countries, 2004

Table 1.12: Healthcare resources in Hungary, the A8 and EU5 countries, 2004

Table 2.13: Pharmaceutical market dynamics across the A8 countries, 2000-04

Table 2.14: Breakdown of sales by therapeutic areas across the EU5 and A8 markets, 2004

Table 2.15: Breakdown of sales by major therapeutic area across EU5, 2000–04

Table 2.16: Breakdown of sales by major therapeutic area across A8, 2000–04

Table 2.17: Sales by major classes across the cardiovascular market in the A8 countries, 2000–

Table 2.18: Sales by A8 country in the cardiovascular market, 2000 and 2004

Table 2.19: Sales by major classes across the CNS market in the A8 countries, 2000–04

Table 2.20: Sales by A8 country in the CNS market, 2000 and 2004

Table 2.21: Sales by major classes across the respiratory market in the A8 countries, 2000–04

Table 2.22: Sales by A8 country in the respiratory market, 2000 and 2004

Table 2.23: Sales by major classes across the anti-infectives market in the A8 countries, 2000–

Table 2.24: Sales by A8 country in the anti-infectives market, 2000-2004

Table 2.25: Sales by major classes across the cancer market in the A8 countries, 2000–04

Table 2.26: Sales by A8 country in the cancer market, 2000-2004

Table 2.27: Sales of other therapeutic categories in the A8 countries, 2000-04

Table 2.28: Sales forecasts for key therapeutic areas in the A8 market, 2004–11

Table 3.29: Sales in the A8 and EU5 pharmaceutical markets by product category, 2000-04

Table 3.30: Sales in the A8 pharmaceutical markets by product category, 2000-04

Table 3.31: Sales in the A8 pharmaceutical markets by product category, 2000-04 (cont.)

Table 3.32: Sales of other brands in the A8 pharmaceutical markets, 2000-04

Table 3.33: Sales of original brands in the A8 pharmaceutical markets, 2000-04

Table 3.34: Sales of licensed brands in the A8 pharmaceutical markets, 2000-04

Table 3.35: Sales of unbranded drugs in the A8 pharmaceutical markets, 2000-04

Table 3.36: Therapeutic sales in the A8 pharmaceutical markets by product category, 2004

Table 3.37: Sales of cardiovascular therapeutics in the A8 pharmaceutical markets by product

category, 2004

Table 3.38: Sales of CNS therapeutics in the A8 pharmaceutical markets by product category,

2004

Table 3.39: Sales of cancer therapeutics in the A8 pharmaceutical markets by product category,

2004

Table 3.40: Sales of anti-infective therapeutics in the A8 pharmaceutical markets by product

category, 2004

viii

Table 3.41: Sales of respiratory therapeutics in the A8 pharmaceutical markets by product

category, 2004

Table 3.42: Sales of other therapeutics in the A8 pharmaceutical markets by product category,

2004

Table 4.43: Sales of leading pharmaceutical companies in the A8 region,

Table 4.44: Zentiva’s sales in the A8 pharmaceutical markets, 2000-04

Table 4.45: Zentiva’s corporate agreements, 2003-2006

Table 4.46: Gedeon Richter’s sales in the A8 pharmaceutical markets, 2000-04

Table 4.47: Gedeon Richter’s corporate agreements, 2000-2006

Table 4.48: KRKA’s sales in the A8 pharmaceutical markets, 2000-04

Table 4.49: KRKA’s corporate agreements, 2000-2006

Table 4.50: Polpharma’s sales in the A8 pharmaceutical markets, 2000-04

Table 4.51: Polpharma’s corporate agreements, 2000-2006

Table 4.52: Pliva’s sales in the A8 pharmaceutical markets, 2000-04

Table 4.53: Pliva’s corporate agreements, 2000-2006

Table 4.54: Novartis’ sales in the A8 pharmaceutical markets, 2000-04

Table 4.55: Novartis’ corporate agreements, 2000-2006

Table 4.56: Sanofi-Aventis’ sales in the A8 pharmaceutical markets, 2000-04

Table 4.57: Sanofi-Aventis’ corporate agreements, 2000-2006

Table 4.58: GSK’s sales in the A8 pharmaceutical markets, 2000-04

Table 4.59: GSK’s corporate agreements, 2000-2006

Table 4.60: Servier’s sales in the A8 pharmaceutical markets, 2000-04

Table 4.61: Servier’s corporate agreements, 2000-2006

Table 4.62: Pfizer’s sales in the A8 pharmaceutical markets, 2000-04 185